These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2681442)

  • 21. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
    Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
    Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
    Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
    J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha.
    Tefferi A; Grendahl DC
    Am J Hematol; 1996 Jul; 52(3):231-3. PubMed ID: 8756097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit.
    Grossberg SE; Kawade Y; Kohase M; Klein JP
    J Interferon Cytokine Res; 2001 Sep; 21(9):743-55. PubMed ID: 11576468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
    Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
    J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
    Corbillet V; Celerier P; Lebon P; Litoux P; Dreno B
    Ann Med Interne (Paris); 1995; 146(6):399-403. PubMed ID: 8597337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors.
    Ross C; Hansen MB; Schyberg T; Berg K
    Clin Exp Immunol; 1990 Oct; 82(1):57-62. PubMed ID: 2119920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
    Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
    J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies.
    Viscomi GC; Antonelli G; Bruno C; Scapol L; Malavasi F; Funaro A; Simeoni E; Pestka S; De Pisa F; Dianzani F
    J Interferon Cytokine Res; 1999 Apr; 19(4):319-26. PubMed ID: 10334382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon-alpha N1 and in vitro studies on the specificity of the antibodies.
    Brand CM; Leadbeater L; Budiman R; Lechner K; Gisslinger H
    Br J Haematol; 1994 Jan; 86(1):216-8. PubMed ID: 8011536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The influence of interferon alpha neutralizing antibodies on the therapeutic effectiveness in patients with chronic viral hepatitis].
    Tong F; Tang Y; Bai J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):345-7. PubMed ID: 12759973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
    Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
    J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.
    Bell JB; Barfoot R; Iveson T; Powles RL; Millar BC
    Br J Cancer; 1994 Oct; 70(4):646-51. PubMed ID: 7917911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a.
    Ross C; Engler CB; Sander B; Bendtzen K
    J Interferon Cytokine Res; 2002 Apr; 22(4):421-6. PubMed ID: 12034024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping.
    Bello-Rivero I; Cervantes M; Torres Y; Ferrero J; Rodríguez E; Pérez J; García I; Díaz G; López-Saura P
    J Autoimmun; 2004 Aug; 23(1):63-73. PubMed ID: 15236754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
    Steis RG; Smith JW; Urba WJ; Venzon DJ; Longo DL; Barney R; Evans LM; Itri LM; Ewel CH
    Blood; 1991 Feb; 77(4):792-8. PubMed ID: 1704264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management.
    Roffi L; Mels GC; Antonelli G; Bellati G; Panizzuti F; Piperno A; Pozzi M; Ravizza D; Angeli G; Dianzani F
    Hepatology; 1995 Mar; 21(3):645-9. PubMed ID: 7875661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.
    Nolte KU; Günther G; von Wussow P
    Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.
    Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G
    Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High levels of circulating neutralizing antibody in normal animals to recombinant mouse interferon-beta produced in yeast.
    Sedmak JJ; Grossberg SE
    J Interferon Res; 1989 Sep; 9 Suppl 1():S61-5. PubMed ID: 2809279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.